SWK Holdings Corp
SWKH
$17.27
Closing
▲0.12%
1D
▼-1.48%
YTD
Market cap
$215.83M
52 week high
$18.29
52 week low
$15.26
Volume
2,091
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$215.83M
Analysts' Rating
BUY
Price Target (Mean)
24
Total Analysts
2
P/E
13.82
Operating Margin
48.27%
Beta
0.40
Revenue Growth (Annual)
-26.13%
52 week high
$18.29
52 week low
$15.26
Div. Yield
%
EPS Annual Growth
16.13
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company’s segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers sophisticated, customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical-stage biopharmaceutical company offering formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. This segment utilizes the technology platform to create a portfolio of royalty income.
